Press Releases

Press Releases

SAN FRANCISCO, March 03, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will
03/03/2021
-Phase 2b NASH trial as part of a potential Phase 2b/3 program expected to initiate in 1H21- -Topline data from recently initiated NASH paired-biopsy, open-label histology cohort expected by YE21- -Topline data from BIO89-100’s Phase 2 SHTG trial expected in 2H21- SAN FRANCISCO, Jan.
01/05/2021
SAN FRANCISCO, Jan. 04, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Rohan Palekar, the
01/04/2021
– Updated clinical data from BIO89-100 ’s Phase 1b/2a NASH trial to be presented as a late-breaking poster at upcoming AASLD Liver Meeting – – Planni ng to initiate the Phase 2b trial as part of the Phase 2b/3 program in NASH in 1H21 – – Topline results from BIO89-100’s Phase 2 SHTG trial expected
11/10/2020
SAN FRANCISCO, Sept. 28, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Rohan Palekar, the
09/28/2020